Cargando…

Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer

Detalles Bibliográficos
Autores principales:	Langerød, A, Zhao, H, Borgan, Ø, Nesland, JM, Hernandez-Boussard, T, Bukholm, IK, Kåresen, R, Børresen-Dale, AL, Jeffrey, SS
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233595/ http://dx.doi.org/10.1186/bcr1174

Ejemplares similares

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
por: Langerød, Anita, et al.
Publicado: (2007)

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer
por: Andersen, TI, et al.
Publicado: (2000)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

TP53 mutations among molecular subtypes of HER2-positive tumors
por: Helland, Å, et al.
Publicado: (2005)

Prognostic significance of TP53 alterations in breast carcinoma.
por: Andersen, T. I., et al.
Publicado: (1993)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer
por: Silwal-Pandit, Laxmi, et al.
Publicado: (2015)

TP53 allele loss, mutations and expression in malignant melanoma.
por: Flørenes, V. A., et al.
Publicado: (1994)

TP53 gene mutations and protein accumulation in primary vaginal carcinomas.
por: Skomedal, H., et al.
Publicado: (1995)

Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients
por: Olivier, M, et al.
Publicado: (2005)

TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
por: Kringen, Pedro, et al.
Publicado: (2005)

Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer
por: Yoshimura, Noriko, et al.
Publicado: (2004)

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway
por: Joshi, H, et al.
Publicado: (2012)

BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations
por: Holstege, Henne, et al.
Publicado: (2010)

Evaluation of the arrayed primer extension resequencing assay for TP53 mutation detection
por: Due, EU, et al.
Publicado: (2005)

Expression of full-length p53 and its isoform Δp53 in breast carcinomas in relation to mutation status and clinical parameters
por: Baumbusch, Lars O, et al.
Publicado: (2006)

Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.
por: Smith-Sørensen, B., et al.
Publicado: (1998)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
por: Halvorsen, Ann R., et al.
Publicado: (2016)

TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
por: Wang, Y, et al.
Publicado: (2004)

Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load.
por: Helland, A., et al.
Publicado: (1998)

Discovery and validation of breast cancer subtypes
por: Kapp, Amy V, et al.
Publicado: (2007)

Discovery and validation of breast cancer subtypes
por: Kapp, Amy V, et al.
Publicado: (2006)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma
por: Boldrin, Elisa, et al.
Publicado: (2023)

EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
por: Pietersen, Alexandra M, et al.
Publicado: (2008)

TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia
por: Maschietto, Mariana, et al.
Publicado: (2014)

Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer
por: Hwang, Hye Jung, et al.
Publicado: (2020)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations
por: Sung, You-Na, et al.
Publicado: (2022)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma
por: Omura, Go, et al.
Publicado: (2017)

Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2015)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
por: Haase, Detlef, et al.
Publicado: (2019)

Construction and Validation of an Immune-Related Prognostic Model Based on TP53 Status in Colorectal Cancer
por: Zhao, Xiaojuan, et al.
Publicado: (2019)

Establishing an 8‐gene immune prognostic model based on TP53 status for lung adenocarcinoma
por: Wu, Guodong, et al.
Publicado: (2022)

The TP53 tumour suppressor gene in colorectal carcinomas. I. Genetic alterations on chromosome 17.
por: Meling, G. I., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_7sdnihd4eb6s402ohtj0iepqdf